BackAgomAb Therapeutics N.V. American Depositary Shares Overview

AgomAb Therapeutics N.V. American Depositary Shares Current Cash

Latest current cash for AGMB: $220M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$221.59M

Peer trimmed avg / median

Loading

AgomAb Therapeutics N.V. American Depositary Shares Current Cash History

Loading

AgomAb Therapeutics N.V. American Depositary Shares vs. peers: Current Cash Comparison

Loading

AgomAb Therapeutics N.V. American Depositary Shares Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) FAQ

As of the most recent data (June 2026), AGMB shows a current cash of $220M. Scroll down for historical charts and peer comparison views.

Tracking AGMB's current cash over time shows whether AgomAb Therapeutics N.V. American Depositary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $220M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has AgomAb Therapeutics N.V. American Depositary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $220M) with ownership activity and broader fundamentals.

AgomAb Therapeutics N.V. American Depositary Shares's current cash is $220M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.